v3.25.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net loss $ (14,873,182) $ (8,007,346)
Depreciation and amortization 4,149,240 4,048,409
Interest from amortization of loan issuance costs 213,829 0
Amortization of fair value of loan 71,215 0
Loss on extinguishment of debt 418,502 0
Change in fair value of warrant liability 1,353,716 0
Change in fair value of acquisition earnout liabilities 1,560,445 0
Loss on disposal of property and equipment 94,860 124,584
Stock-based compensation on stock options, RSUs & RSAs, net 1,043,464 1,019,023
Provision for credit losses (3,014) (4,426)
Change in operating lease assets and liabilities (273,624) 183,393
Inventory write-offs to allowance 143,362 136,676
Deferred taxes (221,977) (121,803)
Changes in operating assets and liabilities, net of acquisitions:    
Trade accounts receivable (2,626,267) 1,498,698
Other current assets 91,027 (131,177)
Inventories (1,385,690) 960,739
Prepaid expenses and deposits (325,915) 133,810
Accounts payable and accrued liabilities 2,238,619 680,457
Net cash (used in) provided by operating activities (8,331,390) 521,037
Cash flows from investing activities:    
Purchase of property and equipment (1,262,302) (2,182,805)
Proceeds from sale of equipment 10,648 0
Proceeds from sale-leaseback of equipment 0 364,710
Acquisition of G5 (18,486,669) 0
Acquisition of Visimid, net of cash acquired 0 (847,141)
Net cash used in investing activities (19,738,323) (2,665,236)
Cash flows from financing activities:    
Proceeds from exercise of stock options 3,175 0
Proceeds from sale of common stock from Employee Stock Purchase Plan 14,385 39,677
Proceeds from issuance of common stock under public equity placement 0 806,332
Proceeds from issuance of common stock under private equity placement, net of fees 437,725 0
Proceeds from issuance of preferred stock under private equity placement, net of fees 18,675,026 0
Proceeds from issuance of warrants under private equity placement 4,620,561 0
Deferred payment for acquisition of Visimid (125,000) 0
Borrowings on loans payable 6,659,596 278,926
Loan issuance costs (597,465) 0
Payments on loans payable (204,100) (2,459,474)
Repayment of finance lease obligations (187,626) (131,901)
Net cash provided by (used in) financing activities 29,296,277 (1,466,440)
Effect of exchange rate on cash and cash equivalents 170,204 (53,583)
Change in cash, cash equivalents and restricted cash 1,396,768 (3,664,222)
Cash, cash equivalents and restricted cash, beginning of period 3,480,268 7,144,490
Cash, cash equivalents and restricted cash, end of period 4,877,036 3,480,268
Supplemental disclosure of cash flow information:    
Interest paid in cash 273,476 196,541
Income taxes paid 206,121 166,858
Supplemental disclosure of non-cash investing & financing activities:    
Purchase of equipment through finance lease arrangements 93,048 396,058
Operating right-of-use assets acquired in exchange for operating lease liabilities 0 92,136
Issuance of common stock for acquisition of Visimid 713,946 486,054
Issuance of common stock for acquisition of G5 4,872,068 0
Accrual of earnout consideration for acquisition of G5 3,536,471 0
Extinguishment of debt in exchange for common stock, preferred stock, warrants and a note $ 3,057,110 $ 0